Effects of Caffeine on Women's Sexual Arousal
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01242046 |
Recruitment Status :
Withdrawn
(Key personnel were reassigned to different project)
First Posted : November 16, 2010
Last Update Posted : May 27, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sexual Behavior | Dietary Supplement: Caffeine Dietary Supplement: Placebo | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Basic Science |
Official Title: | The Effects of Caffeine on Female Genital Arousal |
Arm | Intervention/treatment |
---|---|
Experimental: Caffeine
Participants will ingest a tablet with 400 mg caffeine
|
Dietary Supplement: Caffeine
400 mg of caffeine in tablet form |
Placebo Comparator: Placebo
Participants will ingest an inert placebo tablet
|
Dietary Supplement: Placebo
Inert tablet |
- Sexual arousal [ Time Frame: 15 minutes post administration of drug or placebo ]Vaginal pulse amplitude, as measured by a vaginal photoplethysmograph
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Women aged 18 or older
- Heterosexual
- Experiencing regular menstrual cycles (not more than 1 missed menstrual period in the past 6 months).
- Currently involved in a stable, sexually active relationship.
- Fluent in the English language.
Exclusion Criteria:
- Self-report of sexual aversion or distress; or of distress related to a history of unwanted or coercive sexual contact.
- Perimenopausal or menopausal status, or >1 missed menstrual period in the previous 6 months; or currently pregnant, breastfeeding, or having breastfed within the past 3 months; or clinically significant untreated renal or endocrine disease.
- History of HIV infection or active, untreated pelvic, vaginal, or urinary tract infection including sexually transmitted diseases such as chlamydia, genital herpes, gonorrhea, or syphilis.
- Previous major pelvic surgery that may have caused nerve damage, including hysterectomy, vulvectomy, circumcision, colostomy, cystostomy, or serious bladder, rectal, or abdominal surgery; or neurological impairment due to diabetes, stroke, pelvic nerve damage secondary to trauma, cancer treatments, myasthenia gravis, multiple sclerosis or spinal cord damage.
- Self-report of an untreated psychosis (e.g., bipolar disorder or schizophrenia).
- Women who do not use caffeine products regularly (i.e., on a daily basis).
- Women receiving any of the following medications will be excluded from the study, as they have been shown to alter sexual function or arousal response: Dehydroepiandrosterone (DHEA), testosterone and other androgens, estrogens (except oral contraceptives), progesterone, tamoxifen, raloxifene, and other selective estrogen receptor modulators (SERMs), Beta blockers or other drugs that affect the autonomic nervous system and/or cardiovascular system, any approved or experimental medications or treatments used to enhance the sexual response (e.g., sildenafil), and antidepressants
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01242046
United States, Texas | |
University of Texas at Austin | |
Austin, Texas, United States, 78712 |
Principal Investigator: | Corey A Pallatto, B.A. | University of Texas at Austin |
Responsible Party: | Tierney Kyle Ahrold Lorenz, Researcher, University of Texas at Austin |
ClinicalTrials.gov Identifier: | NCT01242046 |
Other Study ID Numbers: |
2010-07-0070 |
First Posted: | November 16, 2010 Key Record Dates |
Last Update Posted: | May 27, 2015 |
Last Verified: | May 2015 |
female sexual arousal |
Caffeine Central Nervous System Stimulants Physiological Effects of Drugs Phosphodiesterase Inhibitors Enzyme Inhibitors |
Molecular Mechanisms of Pharmacological Action Purinergic P1 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents |